



## Altimune to Participate in Upcoming Investor Conferences

May 27, 2026 at 8:30 AM EDT

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

- **2026 Jefferies Global Healthcare Conference**  
Thursday, June 4, 2026  
Fireside chat at 12:50 p.m. ET  
New York, NY
- **Goldman Sachs 47<sup>th</sup> Annual Global Healthcare Conference**  
Wednesday, June 10, 2026  
Fireside chat at 8:00 a.m. ET  
Miami Beach, FL

A webcast of the fireside chats will be available via the [Events](#) section of the Altimune website.

### About Altimune

Altimune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow [@Altimune, Inc. on LinkedIn](#)

Follow [@AltimuneInc on X](#)

### Investor Contact:

Luis Sanay, CFA  
Vice President, Investor Relations  
[ir@altimmune.com](mailto:ir@altimmune.com)

### Media Contact:

Real Chemistry  
[altimmune@realchemistry.com](mailto:altimmune@realchemistry.com)



Source: Altimune, Inc